1. Patients: Information about CRE [Internet]. 2021 [cited 2021 Dec 7]. Available from: https://www.cdc.gov/hai/organisms/cre/cre-patients.html
2. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19:56–66.
3. Magiorakos AP, Burns K, Rodríguez Baño J, Borg M, Daikos G, Dumpis U, et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrobial Resistance & Infection Control. 2017;6:113.
4. World Health Organization. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in health care facilities. [Internet]. 2017 [cited 2021 Oct 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK493061/
5. Haut Conseil de la Santé Publique. Actualisation des recommandations relatives aux BHRe [Internet]. 2019. Available from: https://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=758
6. Public Health England. Framework of actions to contain carbapenemase-producing Enterobacterales [Internet]. 2020 [cited 2021 Nov 15]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/926563/Framework_of_actions_to_contain_CPE-draft.pdf
7. Sypsa V, Psichogiou M, Bouzala G-A, Hadjihannas L, Hatzakis A, Daikos GL. Transmission dynamics of carbapenemase-producing Klebsiella pneumoniae and anticipated impact of infection control strategies in a surgical unit. PLoS ONE. 2012;7:e41068.
8. Knight GM, Dyakova E, Mookerjee S, Davies F, Brannigan ET, Otter JA, et al. Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals. BMC Med. 2018;16:141.
9. Lapointe-Shaw L, Voruganti T, Kohler P, Thein H-H, Sander B, McGeer A. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients. Eur J Clin Microbiol Infect Dis. 2017;36:1047–55.
10. Bartsch SM, Wong KF, Mueller LE, Gussin GM, McKinnell JA, Tjoa T, et al. Modeling Interventions to Reduce the Spread of Multidrug-Resistant Organisms Between Health Care Facilities in a Region. JAMA Netw Open. 2021;4:e2119212.
11. Kardaś-Słoma L, Lucet J-C, Perozziello A, Pelat C, Birgand G, Ruppé E, et al. Universal or targeted approach to prevent the transmission of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units: a cost-effectiveness analysis. BMJ Open. 2017;7:e017402.
12. Pelat C, Kardaś-Słoma L, Birgand G, Ruppé E, Schwarzinger M, Andremont A, et al. Hand Hygiene, Cohorting, or Antibiotic Restriction to Control Outbreaks of Multidrug-Resistant Enterobacteriaceae. Infect Control Hosp Epidemiol. 2016;37:272–80.
13. Guyot, J.M. Etude sur l’évaluation des pratiques dans le cadre de la lutte contre les infections nosocomiales sur les « frictions hydro-alcooliques par spécialités médico-chirurgicales ». Lot n°2 : Enquête sur le nombre d’opportunités d’hygiène des mains par spécialité médico-chirugicale: Ministère de la Santé, de la Jeunesse et des Sports et de la vie associative, Direction Générale de la Santé, Sous-direction Prévention des risques infectieux; 2008.
14. Vanhems P, Barrat A, Cattuto C, Pinton J-F, Khanafer N, Régis C, et al. Estimating Potential Infection Transmission Routes in Hospital Wards Using Wearable Proximity Sensors. Viboud C, editor. PLoS ONE. 2013;8:e73970.
15. Direction de l’hospitalisation et de l’organisation des soins. Circulaire DHOS/02 no 2007-117 du 28 mars 2007 relative à la filière de soins gériatriques [Internet]. 2020 [cited 2020 Nov 13]. Available from: https://solidarites-sante.gouv.fr/fichiers/bo/2007/07-04/a0040058.htm
16. Jolivet S, Vaillant L, Poncin T, Lolom I, Gaudonnet Y, Rondinaud E, et al. Prevalence of carriage of extended-spectrum β-lactamase-producing enterobacteria and associated factors in a French hospital. Clin Microbiol Infect. 2018;24:1311–4.
17. Otter JA, Dyakova E, Bisnauthsing KN, Querol-Rubiera A, Patel A, Ahanonu C, et al. Universal hospital admission screening for carbapenemase-producing organisms in a low-prevalence setting. J Antimicrob Chemother. 2016;71:3556–61.
18. Birgand G, Leroy C, Nerome S, Luong Nguyen LB, Lolom I, Armand-Lefevre L, et al. Costs associated with implementation of a strict policy for controlling spread of highly resistant microorganisms in France. BMJ Open. 2016;6:e009029.
19. European Centre for Disease Prevention and Control. Antimicrobial resistance interactive database (EARS-Net) [Internet]. 2016 [cited 2016 Sep 6]. Available from: http://ecdc.europa.eu/en/healthtopics/antimicrobial-resistance-and-consumption/antimicrobial_resistance/database/Pages/database.aspx
20. Otter JA, Mookerjee S, Davies F, Bolt F, Dyakova E, Shersing Y, et al. Detecting carbapenemase-producing Enterobacterales (CPE): an evaluation of an enhanced CPE infection control and screening programme in acute care. Journal of Antimicrobial Chemotherapy. 2020;75:2670–6.
21. Saliba R, Neulier C, Seytre D, Fiacre A, Faibis F, Leduc P, et al. Can real-time polymerase chain reaction allow a faster recovery of hospital activity in cases of an incidental discovery of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant Enterococci carriers? Journal of Hospital Infection. 2019;103:115–20.
22. Maechler F, Schwab F, Hansen S, Fankhauser C, Harbarth S, Huttner BD, et al. Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial. The Lancet Infectious Diseases. 2020;20:575–84.
23. Duval A, Obadia T, Boëlle P-Y, Fleury E, Herrmann J-L, Guillemot D, et al. Close proximity interactions support transmission of ESBL-K. pneumoniae but not ESBL-E. coli in healthcare settings. Lloyd-Smith J, editor. PLOS Computational Biology. 2019;15:e1006496.
24. Haverkate MR, Bootsma MCJ, Weiner S, Blom D, Lin MY, Lolans K, et al. Modeling Spread of KPC-Producing Bacteria in Long-Term Acute Care Hospitals in the Chicago Region, USA. Infection Control & Hospital Epidemiology. 2015;36:1148–54.
25. Chia PY, Sengupta S, Kukreja A, S.L. Ponnampalavanar S, Ng OT, Marimuthu K. The role of hospital environment in transmissions of multidrug-resistant gram-negative organisms. Antimicrob Resist Infect Control. 2020;9:29.
26. Jimenez A, Fennie K, Munoz-Price LS, Ibrahimou B, Pekovic V, Abbo LM, et al. Duration of carbapenemase-producing Enterobacteriales carriage among ICU patients in Miami, FL: A retrospective cohort study. Am J Infect Control. 2021;49:1281–6.
27. Otter JA, Burgess P, Davies F, Mookerjee S, Singleton J, Gilchrist M, et al. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect. 2017;23:188–96.
28. De Angelis G, Murthy A, Beyersmann J, Harbarth S. Estimating the impact of healthcare-associated infections on length of stay and costs. Clin Microbiol Infect. 2010;16:1729–35.
29. Birgand G, Schwarzinger M, Perozziello A, Lolom I, Pelat C, Armand-Lefevre L, et al. Prolonged hospital stay, an adverse effect of strict national policy for controlling the spread of highly resistant microorganisms. Infect Control Hosp Epidemiol. 2014;35:1427–9.
30. Schechner V, Kotlovsky T, Kazma M, Mishali H, Schwartz D, Navon-Venezia S, et al. Asymptomatic rectal carriage of blaKPC producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected? Clinical Microbiology and Infection. 2013;19:451–6.
31. ATIH-Agence technique de l’information sur l’hospitalisation. Analyse de l’activité hospitalière [Internet]. 2017 [cited 2019 Jan 15]. Available from: https://www.atih.sante.fr/sites/default/files/public/content/3478/synthese_aah_2017.pdf
32. Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S, et al. Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure? J Antimicrob Chemother. 2016;71:1088–97.
33. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens. Antimicrob Agents Chemother. 2012;56:2108–13.
34. Derde LPG, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJL, Gniadkowski M, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis. 2014;14:31–9.
35. Segagni Lusignani L, Presterl E, Zatorska B, Van den Nest M, Diab-Elschahawi M. Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011–2016) case-control study. Antimicrobial Resistance & Infection Control [Internet]. 2020 [cited 2020 Nov 20];9. Available from: https://aricjournal.biomedcentral.com/articles/10.1186/s13756-019-0668-2
36. Venier AG, Zaro-Goni D, Pefau M, Hauray J, Nunes J, Cadot C, et al. Performance of hand hygiene in 214 healthcare facilities in South-Western France. Journal of Hospital Infection. 2009;71:280–2.
37. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA. 1999;282:1745–51.
38. Mollers M, Lutgens SP, Schoffelen AF, Schneeberger PM, Suijkerbuijk AWM. Cost of Nosocomial Outbreak Caused by NDM-1-Containing Klebsiella pneumoniae in the Netherlands, October 2015-January 2016. Emerging Infect Dis. 2017;23:1574–6.
39. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011;52:848–55.
40. Fournier S, Monteil C, Lepainteur M, Richard C, Brun-Buisson C, Jarlier V, et al. Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012. Eurosurveillance. 2014;19:20802.
41. Cohen MJ, Block C, Levin PD, Schwartz C, Gross I, Weiss Y, et al. Institutional Control Measures to Curtail the Epidemic Spread of Carbapenem-Resistant Klebsiella pneumoniae : A 4-Year Perspective. Infect Control Hosp Epidemiol. 2011;32:673–8.
42. Santé Publique France. Bilan des signalements BHRe 2019 [Internet]. 2020. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-associees-aux-soins-et-resistance-aux-antibiotiques/resistance-aux-antibiotiques/documents/donnees/bilan-bhre-2019
43. Srigley JA, Furness CD, Baker GR, Gardam M. Quantification of the Hawthorne effect in hand hygiene compliance monitoring using an electronic monitoring system: a retrospective cohort study. BMJ Qual Saf. BMJ Publishing Group Ltd; 2014;23:974–80.
44. Hagel S, Reischke J, Kesselmeier M, Winning J, Gastmeier P, Brunkhorst FM, et al. Quantifying the Hawthorne Effect in Hand Hygiene Compliance Through Comparing Direct Observation With Automated Hand Hygiene Monitoring. Infect Control Hosp Epidemiol. 2015;36:957–62.
45. Assistance publique – Hôpitaux de Paris (AP-HP). Base de données PMSI. 2015.
46. Swaminathan M, Sharma S, Blash SP, Patel G, Banach DB, Phillips M, et al. Prevalence and Risk Factors for Acquisition of Carbapenem-Resistant Enterobacteriaceae in the Setting of Endemicity. Infection Control & Hospital Epidemiology. 2013;34:809–17.
47. Bartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clinical Microbiology and Infection. 2017;23:48.e9-48.e16.
48. Daroukh A, Delaunay C, Bigot S, Ceci JM, Siddhoun N, Bukreyeva I, et al. Characteristics and costs of carbapenemase-producing enterobacteria carriers (2012/2013). Médecine et Maladies Infectieuses. 2014;44:321–6.
49. D’Agata EMC, Webb G, Horn M. A mathematical model quantifying the impact of antibiotic exposure and other interventions on the endemic prevalence of vancomycin-resistant enterococci. J Infect Dis. 2005;192:2004–11.
50. Almagor J, Temkin E, Benenson I, Fallach N, Carmeli Y, on behalf of the DRIVE-AB consortium. The impact of antibiotic use on transmission of resistant bacteria in hospitals: Insights from an agent-based model. Zhou Z, editor. PLOS ONE. 2018;13:e0197111.
51. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerging Infect Dis. 2014;20:1170–5.
52. Austin DJ, Bonten MJ, Weinstein RA, Slaughter S, Anderson RM. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci USA. 1999;96:6908–13.
53. Borer A, Saidel-Odes L, Eskira S, Nativ R, Riesenberg K, Livshiz-Riven I, et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae. American Journal of Infection Control. 2012;40:421–5.
54. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clinical Microbiology and Infection. 2014;20:862–72.
55. Adams DJ, Susi A, Nylund CM. Clinical characteristics, risk factors, and outcomes of patients hospitalized in the US military health system with carbapenem-resistant Enterobacteriaceae infection. American Journal of Infection Control. 2020;48:644–9.
56. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. Journal of Antimicrobial Chemotherapy. 2015;70:2133–43.
57. Tato M, Ruiz-Garbajosa P, Traczewski M, Dodgson A, McEwan A, Humphries R, et al. Multisite Evaluation of Cepheid Xpert Carba-R Assay for Detection of Carbapenemase-Producing Organisms in Rectal Swabs. Carroll KC, editor. Journal of Clinical Microbiology. 2016;54:1814–9.
58. Dortet L, Fusaro M, Naas T. Improvement of the Xpert Carba-R Kit for the Detection of Carbapenemase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. 2016;60:3832–7.
59. Hoyos-Mallecot Y, Ouzani S, Dortet L, Fortineau N, Naas T. Performance of the Xpert ® Carba-R v2 in the daily workflow of a hygiene unit in a country with a low prevalence of carbapenemase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents. 2017;49:774–7.
60. Harris AD. Universal Glove and Gown Use and Acquisition of Antibiotic-Resistant Bacteria in the ICU: A Randomized Trial. JAMA [Internet]. 2013 [cited 2021 Jan 15]; Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2013.277815